Latest news with #BayerAG
Forbes
a day ago
- Business
- Forbes
20 Underrated Qualities Of Great Marketing And Comms Leaders
getty It's easy to spotlight bold ideas or big wins when evaluating a marketing and communications leader. However, the attributes that make someone truly effective in a comms leadership role are often less flashy, and far more influential, than many people may realize. Cultivating traits like genuine listening, composure under pressure and emotional intelligence can help a leader quietly shape how their team performs and how a brand is perceived. Below, 20 Forbes Communications Council members discuss underrated qualities of great marketing and comms leaders and how they help them drive real impact throughout their organizations. Leaders in communications and marketing need to face adversity with a mindset geared toward growth. Positively resilient leaders are flexible in their thinking and behavior, quickly adjusting to changing circumstances. That strengthens creativity and fosters a culture of experimentation, which leads to individual growth for team members and organizational growth. - Diana Scholz, Bayer AG As a communications leader, you must often make informed recommendations that go against others' opinions. It is an uncomfortable place to be, but seasoned practitioners know that never challenging the status quo can eventually cause negative brand impact. Where this skill is valued, a brand will succeed; where opinion matters more than expertise, time will show the true implications. - Aleka Bhutiani, Golub Capital The most underrated quality is humility. Great teams shine when the leader takes a step back. Instead of trying to be the smartest person in the room, focus on hiring the smartest people. By hiring an impressive team and letting them have autonomy, you create space for new perspectives that will ultimately produce something that one person would be incapable of producing alone. - Layla Kasha, Grocery Outlet We tend to equate leadership with having all the answers, but truly exceptional leaders are those who masterfully absorb the insights of their teams and the needs of the organizations they serve. This isn't passive hearing; it's active engagement that drives teams to articulate their perspectives freely and align solutions with goals. - Kayla Spiess, Searce Forbes Communications Council is an invitation-only community for executives in successful public relations, media strategy, creative and advertising agencies. Do I qualify? Relational intelligence, or RQ, is the ability to understand and manage relationships, including those with oneself, others and the world, and it is a pivotal quality for any leader, but especially for marketing and communications leaders. Since both areas are ultimately about people and connection, RQ helps these leaders make a meaningful impact for both their teams and their companies. - John Jorgenson, Cambium Learning Group Empathy allows leaders to understand the audience's needs and desires, which helps in addressing messages that resonate and connect. It improves the work environment and creates better teamwork, leading to a more resilient team. - Khalid Al Awar, Dubai Sports Council Adaptability is an underrated quality in a leader. The ability to pivot quickly in response to market shifts, new platforms, AI and fresh talent creates resilient teams. If a company resists all those shifts, it may remain stagnant, while those that embrace them turn those shifts into competitive advantages. - Persa Sakellaridi, Wikifarmer The most underrated quality in marketing leadership is intellectual humility. Leaders who admit uncertainty while maintaining direction create spaces where innovation thrives. Teams respond with bolder ideas and adapt quickly. In our evolving influencer ecosystem, this quality transforms agencies from rigid hierarchies into creative hubs where both people and strategies can breathe and evolve. - Jaime Hintz, Cogent World The most undervalued skill is vision with discernment—the ability to see what's on the horizon and know what matters most. It allows teams to act, rather than react. With guidance and sound judgment, leaders build trust, encourage more informed decision-making and make sustainable progress in an ever-changing world. - Melissa Sierra, USIM It's what author Brad Stulberg calls 'rugged flexibility' in his book Master of Change: the ability to stay grounded in purpose and values while adapting to change. In a field defined by constant shifts, this mindset helps leaders navigate ambiguity and model resilience. The result is a culture that thrives in flux—a culture that is responsive, focused and effective even in uncertain times. - Amber Roussel Cavallo, Civic Builders An important quality in a leader is cross-functional fluency. Many overlook how critical it is for a marketing leader to speak the language of finance, tech and operations. This isn't about being a generalist—it's about being understood. Leaders who can bridge disciplines align faster, influence deeper and earn a seat at the table where real decisions are made. - Janita Pannu, OPIIA Inc. Great leaders in marketing and communications don't just craft poignant and effective messaging for external audiences; they also know how to connect directly with their internal team. The key to building that connection is through consistent updates on important organizational developments. This level of transparency is valuable because it drives stronger collaboration and helps teams feel more invested in the company. - Victoria Zelefsky, Anne Arundel Economic Development Corporation The most underrated trait of a great leader is strategic focus. Effective leaders are able to keep their eyes on meaningful outcomes rather than high-volume activities. They prioritize initiatives that deliver real value and have the discipline to say 'no' to time-consuming projects without benefits. The result is less team burnout and more sustainable company growth. - Rekha Thomas, Path Forward Marketing A highly underrated trait in marketing leaders is comfort with uncertainty. True leadership shows in moments of ambiguity by staying composed, guiding teams through change and fostering a culture of innovation. This steadiness inspires confidence, enabling teams to act boldly and drive meaningful impact. - Lauren Parr, RepuGen Visual storytelling is an underrated quality of some communications leaders. Our brains process images faster than text, so I challenge my team to pass the 'Japanese 80/20 test,' a standard I coined: 'If this asset were in a foreign language, would the audience still grasp 80% of the meaning through visuals alone?' This lens sharpens clarity, drives impact and ensures your message lands before a single word is read. - Stephanie Bunnell, Azira I believe emotional intelligence is the most underrated quality of a great marketing leader. It fosters empathy, improves communication and builds trust within the team. Leaders who understand and manage emotions effectively create an environment where creativity thrives, collaboration is seamless and teams feel valued, ultimately driving better outcomes for the company. - Barbara Puszkiewicz-Cimino, SUMMIT One Vanderbilt I believe the most underrated quality of a great leader is empathy. Great marketing leaders understand their audience, team and clients. In my case, I empathize because I have been there. This emotional intelligence drives authentic storytelling, fosters trust and aligns messaging with purpose. This leads to stronger connections, empowered teams and marketing that actually moves people. - Rich Bornstein, Bornstein Media The ability to 'professionally schmooze'—that is, to read people and tailor communication in real time—is live audience targeting and an underrated yet essential skill. It builds trust, aligns messaging and turns interactions into strategic wins. That and emotional intelligence transform ideas into influence and separate strong creatives from exceptional leaders. - Lyric Mandell, PhD, MOXY Company The most underrated quality of a great marketing leader is the capability to foster psychological safety. When team members feel safe to share ideas without fear of judgment, creativity thrives. Leaders who prioritize this environment encourage open dialogue, leading to innovative strategies and more resonant campaigns. This builds stronger teams and drives impactful work that elevates the brand. - Katie Jewett, UPRAISE Marketing + Public Relations CMOs are undervalued as multidimensional value creators fueling revenue, relevance, growth, innovation and reputation. They translate cultural, consumer and stakeholder signals into strategic foresight. Boards biased toward CFOs and COOs as members over board-ready CMOs with P&L experience miss both risks and opportunities in brand equity, stakeholder trust and enterprise value. - Toby Wong, Toby Wong Consulting
Associated Press
27-05-2025
- Business
- Associated Press
AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson's Disease in Movement Disorders
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced today the recent publication of the complete results of its Phase 1b trial of AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy for the treatment of Parkinson's disease (PD), in Movement Disorders, an official peer-reviewed journal of the International Parkinson and Movement Disorder Society.1 'The exploration of the neurorestorative and neuroprotective potential of GDNF gene transfer is critical to advancing our understanding of AB-1005, which may one day be a groundbreaking treatment to slow the progression of Parkinson's disease,' said Chad Christine, MD, Professor of Neurology at the University of California, San Francisco, and publication author. 'These encouraging results support further evaluation of this therapy in a randomized trial.' The publication, which is available online, states that treatment with AB-1005 was well tolerated with no serious adverse events related to GDNF gene therapy in all 11 participants and is associated with numerical stability in clinical assessment readouts (mild cohort) and improvement (moderate cohort) in clinical assessments of motor function at 18 months post-gene transfer. In addition to these data, which were first presented in April 2024 at the American Academy of Neurology Annual Meeting, the publication notes that non-motor assessments remained numerically stable throughout the 18-month follow-up in the mild and moderate cohorts. Stability findings may be an indication of the potential for AB-1005 to positively affect disease progression.1,2 'These results support the continued study of AB-1005 as a potential gene therapy to slow the progression of Parkinson's disease,' said Lila Collins, PhD, Associate Director of Portfolio Development & Review at the California Institute for Regenerative Medicine. 'We are pleased to have supported this important trial and look forward to AskBio's Phase 2 REGENERATE-PD results, which will provide additional insights into the durability of the clinical response and potential disease-modifying effect of AB-1005.' In February 2025, AB-1005 was granted Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration.3 AB-1005 is an investigational gene therapy that has not been approved by any regulatory authority, and its efficacy and safety have not been fully established or evaluated. About Parkinson's disease Parkinson's disease (PD) is a progressive neurodegenerative disease.4 It has a significant impact on a person's daily life.4 In PD, the death of dopamine-producing nerve cells in the brain leads to the continuous loss of motor function.5 Symptoms include tremors, muscle rigidity, and slowness of movement.6 Additionally, people with PD experience non-motor symptoms, including fatigue and lack of energy, cognitive issues, and depression.6 Symptoms typically intensify over time and make everyday tasks increasingly demanding.6 The prevalence of PD has doubled over the past 25 years.4 Today, more than 10 million people worldwide are estimated to be living with PD.7 This makes it the world's second most prevalent neurodegenerative disease.8 It is also the most frequent movement disorder.4,9 At present there is no cure, and current treatment options lack the holistic management of symptoms, so new therapies are needed.10 About the AB-1005 Phase 1b trial In this Phase 1b, multicenter, multisite, open-label, uncontrolled trial, 11 participants were administered AB-1005 to the putamen via one-time bilateral convection-enhanced delivery. Participants were enrolled into two cohorts, mild (6 participants) and moderate (5 participants), based upon the duration and stage of their Parkinson's disease (PD).11 The objective of this investigation was to evaluate the safety and potential clinical effect of AB-1005 delivered to the putamen in participants with early/mild or moderate PD. The outcomes assessed at 36 months were incidence of treatment-emergent adverse events (TEAEs) as reported by the participants or assessed clinically by physical and neurological examinations, motor symptoms as reported via the Movement Disorder Society's Unified Parkinson's Disease Rating Scale (MDS-UPDRS), and PD Motor Diary self-assessments, non-motor symptoms of PD, and brain dopaminergic network integrity as measured by DaTSCAN.11 These assessments will continue for up to five years. For more information, visit ( NCT04167540 or ). About REGENERATE-PD REGENERATE-PD is a Phase 2, randomized, double-blind, sham-controlled trial of the efficacy and safety of intraputaminal AB-1005 in the treatment of adults (45–75 years) with moderate-stage Parkinson's disease. The trial will include an estimated 87 participants with trial sites located in Germany, Poland, United Kingdom, and United States.12 For more information about the REGENERATE-PD clinical trial, visit ( NCT06285643 or visit ). About AB-1005 AB-1005 is an investigational gene therapy based on adeno-associated viral vector serotype 2 (AAV2) containing the human glial cell line-derived neurotrophic factor (GDNF) transgene, which allows for stable and continuous expression of GDNF in localized regions of the brain after direct neurosurgical injection with convection-enhanced delivery.13,14 In nonclinical studies, GDNF has been shown to promote the survival and morphological differentiation of dopaminergic neurons.14,15 Recombinant GDNF has long been evaluated as a potential treatment for diseases, such as Parkinson's disease (PD), marked by progressive degeneration of midbrain dopaminergic neurons.16 Through a combination of an investigational gene therapy and innovative neurosurgical delivery approach, we can now test the GDNF hypothesis in PD by getting this neurotrophic factor to these degenerating nigrostriatal neurons in a potentially more clinically relevant fashion.16 About AskBio AskBio Inc., a wholly owned and independently operated subsidiary of Bayer AG, is a fully integrated gene therapy company dedicated to developing life-saving medicines and changing lives. The company maintains a portfolio of clinical programs across a range of neuromuscular, central nervous system, cardiovascular, and metabolic disease indications with a clinical-stage pipeline that includes investigational therapeutics for congestive heart failure, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson's disease, and Pompe disease. AskBio's gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive array of capsids and promoters. With global headquarters in Research Triangle Park, North Carolina, United States, the company has generated hundreds of proprietary capsids and promoters, several of which have entered pre-clinical and clinical testing. An early innovator in the gene therapy field, with over 900 employees in five countries, the company holds more than 600 patents and patent applications in areas such as adeno-associated virus (AAV) production and chimeric capsids. Learn more at or follow us on LinkedIn. About Bayer Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to AskBio Forward-Looking Statements This press release contains 'forward-looking statements.' Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'will,' 'intends,' 'potential,' 'possible,' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding AskBio's clinical trials. These forward-looking statements involve risks and uncertainties, many of which are beyond AskBio's control. Known risks include, among others: AskBio may not be able to execute on its business plans and goals, including meeting its expected or planned clinical and regulatory milestones and timelines, its reliance on third-parties, clinical development plans, manufacturing processes and plans, and bringing its product candidates to market, due to a variety of reasons, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved in a timely manner, potential disagreements or other issues with our third-party collaborators and partners, and regulatory, court or agency feedback or decisions, such as feedback and decisions from the United States Food and Drug Administration or the United States Patent and Trademark Office. Any of the foregoing risks could materially and adversely affect AskBio's business and results of operations. You should not place undue reliance on the forward-looking statements contained in this press release. AskBio does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof. References [1] Van Laar A, et al. Intraputaminal Delivery of Adeno-Associated Virus Serotype 2–Glial Cell Line–Derived Neurotrophic Factor in Mild or Moderate Q2 Parkinson's Disease. Mov Disord, 2025. Open access available at: [2] Van Laar, A et al. Phase 1b Safety and Preliminary Efficacy of Bilateral Intraputaminal Delivery of AAV2 GDNF (AB-1005) in Participants With Mild or Moderate Parkinson's Disease. American Academy of Neurology Annual Meeting 2024., presentation 001. Available at: Accessed May 2025. [3] AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson's disease investigational gene therapy. Available at: Accessed May 2025. [4] World Health Organization. Parkinson Disease. Available at: Accessed May 2025. [5] Ramesh S & Arachchige A. Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS Neurosci. 2023 Aug 14;10(3):200-231. [6] National Institutes of Health. Parkinson's Disease. Available at: Accessed: May 2025. [7] Maserejian N, et al. Estimation of the 2020 Global Population of Parkinson's Disease (PD). MDS Virtual Congress 2020. Abstract number 198. Available at: Accessed May 2025. [8] National Institute of Environmental Health Sciences. Neurodegenerative Diseases. Available at: Accessed May 2025. [9] Stoker T & Barker R. Recent developments in the treatment of Parkinson's Disease. F1000Res. 2020 Jul 31;9:F1000 Faculty Rev-862. [10] Mayo Clinic. Parkinson's disease. Available at: Accessed: May 2025. [11] GDNF Gene Therapy for Parkinson's Disease. Available at: Accessed May 2025. [12] A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD). Available at: Accessed May 2025. [13] Heiss J, et al. Trial of magnetic resonance-guided putaminal gene therapy for advanced Parkinson's disease. Mov Disord. 2019 Jul;34(7):1073-1078. [14] Kells A, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci. 2010 Jul 14;30(28):9567-77. [15] Lin L, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260(5111):1130-1132. [16] Barker R, et al. GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020;10(3):875-891. Phil McNamara AskBio Inc. (AskBio) +1 (984) 5207211 [email protected]
Toronto Star
23-05-2025
- Business
- Toronto Star
OTC Markets Group Welcomes Bayer AG to OTCQX
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bayer AG (Frankfurt Stock Exchange: BAYN; OTCQX: BAYRY, BAYZF), a life science company with three divisions – Pharmaceuticals, Consumer Health and Crop Science, has qualified to trade on the OTCQX® Best Market. Bayer AG upgraded to OTCQX from the Pink® market. Bayer AG begins trading today on OTCQX under the symbols 'BAYRY' and 'BAYZF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on
Hamilton Spectator
23-05-2025
- Business
- Hamilton Spectator
OTC Markets Group Welcomes Bayer AG to OTCQX
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bayer AG (Frankfurt Stock Exchange: BAYN; OTCQX: BAYRY, BAYZF), a life science company with three divisions – Pharmaceuticals, Consumer Health and Crop Science, has qualified to trade on the OTCQX® Best Market. Bayer AG upgraded to OTCQX from the Pink® market. Bayer AG begins trading today on OTCQX under the symbols 'BAYRY' and 'BAYZF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on . Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws. 'We are thrilled to welcome Bayer to OTCQX,' said Jason Paltrowitz, OTC Markets EVP of Corporate Services. 'This milestone highlights the continued interplay between the European capital markets and U.S. investors seeking new investment opportunities.' About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to . About OTC Markets Group Inc. OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market, and Pink® Open Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATSTM are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit . Subscribe to the OTC Markets RSS Feed Media Contact: OTC Markets Group Inc., +1 (212) 896-4428, media@
Yahoo
23-05-2025
- Business
- Yahoo
OTC Markets Group Welcomes Bayer AG to OTCQX
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Bayer AG (Frankfurt Stock Exchange: BAYN; OTCQX: BAYRY, BAYZF), a life science company with three divisions – Pharmaceuticals, Consumer Health and Crop Science, has qualified to trade on the OTCQX® Best Market. Bayer AG upgraded to OTCQX from the Pink® market. Bayer AG begins trading today on OTCQX under the symbols 'BAYRY' and 'BAYZF.' U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on Upgrading to the OTCQX Market is an important step for companies seeking to provide transparent trading for their U.S. investors. For companies listed on a qualified international exchange, streamlined market standards enable them to utilize their home market reporting to make their information available in the U.S. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance and demonstrate compliance with applicable securities laws. 'We are thrilled to welcome Bayer to OTCQX,' said Jason Paltrowitz, OTC Markets EVP of Corporate Services. 'This milestone highlights the continued interplay between the European capital markets and U.S. investors seeking new investment opportunities." About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, 'Health for all, Hunger for none,' the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to About OTC Markets Group Inc. OTC Markets Group Inc. (OTCQX: OTCM) operates regulated markets for trading 12,000 U.S. and international securities. Our data-driven disclosure standards form the foundation of our three public markets: OTCQX® Best Market, OTCQB® Venture Market, and Pink® Open Market. Our OTC Link® Alternative Trading Systems (ATSs) provide critical market infrastructure that broker-dealers rely on to facilitate trading. Our innovative model offers companies more efficient access to the U.S. financial markets. OTC Link ATS, OTC Link ECN, OTC Link NQB, and MOON ATSTM are each an SEC regulated ATS, operated by OTC Link LLC, a FINRA and SEC registered broker-dealer, member SIPC. To learn more about how we create better informed and more efficient markets, visit Subscribe to the OTC Markets RSS Feed Media Contact:OTC Markets Group Inc., +1 (212) 896-4428, media@ in to access your portfolio
